Assessment of proliferative potentials of canine osteosarcomas and chondrosarcomas by MIB-1 immunohistochemistry and bromodeoxyuridine incorporation.
The proliferative potential of 17 canine osteosarcomas (OSs) (13 osteoblastic, two anaplastic, one fibroblastic and one chondroblastic), 18 chondrosarcomas (CSs) (13 mesenchymal and five ordinary), three osteomas, and one chondroma was evaluated immunohistochemically by labelling Ki-67 antigen with MIB-1 antibody, and incorporated bromodeoxyuridine (BrdU) with anti-BrdU antibody. The location of BrdU-positive cells in OSs and CSs was similar to that of MIB-1 positive cells, and the mean value of the BrdU labelling index (BrdU LI) and the MIB-1 positive index (MIB-1 PI) in each case were significantly correlated (rs = 0.942, P < 0.05 with Spearman rank correlation coefficient; r = 0.779 P < 0.05 with linear regression analysis). The mean MIB-1 PI of OSs was 29.5%, which was approximately 2.5 times that of CSs, and the highest MIB-1 PI was 34.8% +/- 1.8 S.E.M. in areas without osteoid. In CS cases, the survival rate after 24 months was significantly higher than in OS cases. The high MIB-1 PI therefore supports the view that OSs are clinically more aggressive than CSs in dogs. On the other hand, the highest MIB-1 PI values of mesenchymal CS components occurred in transitional areas, which were composed of poorly differentiated cells embedded in a myxomatous matrix between the chondroidal and mesenchymal regions. The MIB-1 PI was 21.3% +/- 3.0 S.E.M. P < 0.001 in transitional areas. Proliferative markers may be useful in diagnosis and prognosis.
Ohta
G
G
Department of Veterinary Pathology, Faculty of Agriculture, Gifu University, 1-1 Yanagido, Gifu 501-1193, Japan.
Sakai
H
H
Kachi
S
S
Hirata
A
A
Yonemaru
K
K
Kitajima
A
A
Yanai
T
T
Masegi
T
T
D000818:Animals; D014408:Biomarkers, Tumor / Q000032:analysis; D001973:Bromodeoxyuridine; D002813:Chondrosarcoma / Q000473:pathology* / Q000662:veterinary*; D004285:Dogs; D005260:Female; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000378:metabolism*; D008297:Male; D012516:Osteosarcoma / Q000473:pathology* / Q000662:veterinary*; D011379:Prognosis
D014408:Biomarkers, Tumor; D019394:Ki-67 Antigen; D001973:Bromodeoxyuridine